CARDIOVASCULAR EFFICACY AND SAFETY OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS: A META-ANALYSIS OF CARDIOVASCULAR OUTCOME TRIALS

Dimitrios Ioannis Patoulias, Aristi Boulmpou, Eleftherios Teperikidis, Alexandra Katsimardou, Fotios Siskos, Michael Doumas, Christodoulos E Papadopoulos, Vassilios Vassilikos

ORCID number: Dimitrios Ioannis Patoulias 0000-0002-6899-684X; Aristi Boulmpou 0000-0002-5008-114X; Eleftherios Teperikidis 0000-0002-2146-1194; Alexandra Katsimardou 0000-0002-9180-6071; Fotios Siskos 0000-0002-4362-2219; Michael Doumas 0000-0002-7269-8044; Christodoulos E Papadopoulos 0000-0001-9643-9066; Vassilios Vassilikos 0000-0002-6982-4425.

Author contributions: Patoulias DI and Doumas M conceived and designed the study; Patoulias DI, Boulmpou A and Teperikidis E collected and analyzed data; Patoulias DI, Boulmpou A and Siskos F performed study quality and risk of bias assessment; Patoulias DI, Boulmpou A, Katsimardou A and Papadopoulos CE wrote the first draft of the study; Doumas M and Vassilikos V critically revised the final draft.

Conflicts of interest statement: The authors declare no conflict of interest.

PRISMA 2009 Checklist statement: The present meta-analysis was conducted according to 2009 PRISMA Guidelines.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external experts.

Abstract

BACKGROUND
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a generally safe and well tolerated antidiabetic drug class with proven efficacy in type 2 diabetes mellitus (T2DM). Recently, a series of large, randomized controlled trials (RCTs) addressing cardiovascular outcomes with DPP-4 inhibitors have been published.

AIM
To pool data from the aforementioned trials concerning the impact of DPP-4 inhibitors on surrogate cardiovascular efficacy outcomes and on major cardiac arrhythmias.

METHODS
We searched PubMed and grey literature sources for all published RCTs assessing cardiovascular outcomes with DPP-4 inhibitors compared to placebo until October 2020. We extracted data concerning the following “hard” efficacy outcomes: fatal and non-fatal myocardial infarction, fatal and non-fatal stroke, hospitalization for heart failure, hospitalization for unstable angina, hospitalization for coronary revascularization and cardiovascular death. We also extracted data regarding the risk for major cardiac arrhythmias, such as atrial fibrillation, atrial flutter, ventricular fibrillation and ventricular tachycardia.

RESULTS
We pooled data from 6 trials in a total of 52520 patients with T2DM assigned either to DPP-4 inhibitor or placebo. DPP-4 inhibitors compared to placebo led to
Cardiac and cardiovascular systems

Country/Territory of origin: Greece

Key Words: Dipeptidyl peptidase-4 inhibitors; Cardiovascular outcomes; Atrial fibrillation; Atrial flutter; Type 2 diabetes mellitus

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The antidiabetic efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors has already been proven in recently published large randomized controlled trials. The purpose of the present meta-analysis was to clarify the impact of antidiabetic therapy with DPP-4 inhibitors on surrogate cardiovascular outcomes, and to elucidate the effect of these drugs on major cardiac arrhythmias. According to our analysis, this drug class does not significantly affect the risk for any of the addressed cardiovascular outcomes; however, it increases the risk for atrial flutter compared to placebo.

Citation: Patoulias DI, Boulmpou A, Teperikidis E, Katsimardou A, Siskos F, Doumas M, Papadopoulos CE, Vassilikos V. Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials. World J Cardiol 2021; 13(10): 585-592
URL: https://www.wjgnet.com/1949-8462/full/v13/i10/585.htm
DOI: https://dx.doi.org/10.4330/wjc.v13.i10.585

INTRODUCTION

It is well-established that type 2 diabetes mellitus (T2DM) represents an independent risk factor for the development of cardiovascular disease, which accounts for half of deaths among diabetic patients[1]. Patients with T2DM experience higher incidence of vascular interventions compared to high-risk patients without T2DM or cardiovascular disease at baseline, underscoring the necessity for targeted therapeutic interventions[2]. In addition, development of cardiovascular complications among patients with T2DM boosts medical costs, leading to an unbearable economic burden [3]. Besides major adverse cardiovascular events, patients with T2DM experience an increased risk of heart rhythm disorders, nevertheless the exact mechanisms of arrhythmogenesis in the context of T2DM are still under investigation[4].

Dipeptidyl peptidase-4 (DPP-4) inhibitors constitute a safe treatment option with adequate glycemic efficacy in T2DM. However, their cardiovascular efficacy has been assessed in randomized controlled trials[5]. The antidiabetic efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors has already been proven in recently published large randomized controlled trials[6]. The purpose of the present meta-analysis was to clarify the impact of antidiabetic therapy with DPP-4 inhibitors on surrogate cardiovascular outcomes, and to elucidate the effect of these drugs on major cardiac arrhythmias. According to our analysis, this drug class does not significantly affect the risk for any of the addressed cardiovascular outcomes; however, it increases the risk for atrial flutter compared to placebo.
doubted over recent years, after the publication of relevant cardiovascular outcome trials. Previous meta-analyses failed to show any cardiovascular benefit with their use in patients with T2DM\[5-7\]. Since then, additional randomized controlled trials addressing “hard” cardiovascular outcomes with DPP-4 inhibitors have been published. Therefore, we sought to update and extend these meta-analyses, by incorporating all relevant data from published cardiovascular outcome trials until October 2020. In addition, we planned to assess the effect of DPP-4 inhibitors on major cardiac arrhythmias, since there are no relevant studies published in the literature so far.

MATERIALS AND METHODS

Our meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We searched PubMed database and grey literature sources form inception to October 2020, in order to identify relevant cardiovascular outcome trials assessing the cardiovascular efficacy and safety of DPP-4 inhibitors in patients with T2DM. Our inclusion criteria were: (1) Randomized controlled trials; (2) Enrollment of patients with T2DM; (3) Enrollment of adult patients; and (4) Assessment of at least one cardiovascular outcome of interest. Our exclusion criteria were: (1) Observational studies; (2) Studies enrolling patients with type 1 diabetes mellitus; and (3) Studies enrolling children or adolescents.

We utilized the following search terms: “DPP-4 inhibitor”, “dipeptidyl peptidase-4 inhibitor”, “vildagliptin”, “sitagliptin”, “alogliptin”, “linagliptin”, “saxagliptin”, “omarigliptin”, “teneligliptin”, “evogliptin”, “gliptin”, “cardiovascular outcome”, “cardiac arrhythmia”, “atrial fibrillation” combined with the use of Boolean operators “AND” and “OR”. We used both free-text words and MeSH terms. We did not imply any filter regarding study setting, study sample, language or publication date. Unfortunately, we did not registered prospectively our protocol in a publicly available repository.

After de-duplication and assessment of eligible studies at title and abstract level for potential inclusion, two independent reviewers (D.P. and E.T.) extracted the data from the eligible reports, by using a pilot tested, data extraction form. We assessed the following cardiovascular efficacy outcomes: fatal and non-fatal myocardial infarction, fatal and non-fatal stroke, hospitalization for heart failure, hospitalization for unstable angina, hospitalization for coronary revascularization and cardiovascular death. We also assessed the risk for the following cardiac arrhythmias with DPP-4 inhibitor treatment compared to placebo or active comparator: atrial fibrillation, atrial flutter, atrial tachycardia, ventricular fibrillation, ventricular tachycardia, ventricular extrasystoles, supraventricular tachycardia, sinus node dysfunction, second degree atrioventricular block, complete atrioventricular block.

As we assessed only dichotomous variables, differences were calculated with the use of risk ratio (RR), with 95% confidence interval (CI), after implementation of the Mantel-Haenszel random effects formula. Statistical heterogeneity among studies was assessed by using $I^2$ statistics. Heterogeneity was considered to be low if $I^2$ was between 0% and 25%, moderate if $I^2$ was between 25% and 50%, or high if $I^2$ was greater than 75%\[8\]. All analyses were performed at the 0.05 significance level, while they were undertaken with RevMan 5.3 software.

Two independent reviewers (D.P. and A.B.) assessed the quality of the included RCTs, by using the Revised Cochrane risk of bias tool for randomized trials (RoB 2.0) for the primary efficacy outcome\[9\]. Discrepancies between reviewers were solved by discussion, consensus or arbitration by a third senior reviewer (V.V.).

RESULTS

We finally pooled data from six trials in a total of 52520 patients\[10-15\]. Overall risk of bias was considered as low across all selected trials.

DPP-4 inhibitor treatment did not significantly affect any of the prespecified cardiovascular efficacy outcomes. More specifically, DPP-4 inhibitors compared to control led to a non-significant increase in the risk for fatal and non-fatal myocardial infarction (RR = 1.02, 95%CI: 0.94-1.11, $F = 0\%$), hospitalization for heart failure (RR = 1.09, 95%CI: 0.92-1.29, $F = 65\%$) and cardiovascular death (RR = 1.02, 95%CI: 0.93-1.11, $F = 0\%$), as shown in Figures 1A, 1C and 1F. In addition, DPP-4 inhibitors produced a non-significant decrease in the risk for fatal and non-fatal stroke (RR = 0.96, 95%CI:
### Cardiovascular Efficacy of Dipeptidyl-Peptidase-4 Inhibitors

#### A

| Study or Subgroup | DPP-4 Inhibitor | Control | Risk Ratio M-H, Random, 95% CI | Risk Ratio M-H, Random, 95% CI |
|-------------------|-----------------|---------|--------------------------------|--------------------------------|
| CARMELINA         | 165 3494        | 146 3485 | 1.13 [0.91, 1.40] |                                  |
| CAROLINA          | 153 3023        | 149 3010 | 1.03 [0.83, 1.28] |                                  |
| EXAMINE           | 187 2701        | 173 2679 | 1.07 [0.88, 1.31] |                                  |
| NCT01703208      | 52 2092         | 60 2100  | 0.87 [0.60, 1.25] |                                  |
| SAVOR-TIMI 53    | 234 8240        | 236 8173 | 0.98 [0.82, 1.18] |                                  |
| TECOS             | 269 7257        | 276 7266 | 0.98 [0.83, 1.15] |                                  |
| **Total (95% CI)** | **26807**       | **26713** | 1.02 [0.94, 1.11] |                                  |
| Total events      | 1060            | 1039    |                                |                                  |

Heterogeneity: Tau² = 0.00, Chi² = 2.21, df = 5 (P = 0.82); I² = 0%

Test for overall effect: Z = 0.39 (P = 0.69)

#### B

| Study or Subgroup | DPP-4 Inhibitor | Control | Risk Ratio M-H, Random, 95% CI | Risk Ratio M-H, Random, 95% CI |
|-------------------|-----------------|---------|--------------------------------|--------------------------------|
| CARMELINA         | 81 3494         | 88 3485  | 0.92 [0.68, 1.24] |                                  |
| CAROLINA          | 104 3023        | 120 3010 | 0.86 [0.67, 1.12] |                                  |
| EXAMINE           | 29 2701         | 32 2679  | 0.90 [0.55, 1.48] |                                  |
| NCT01703208      | 32 2092         | 34 2100  | 0.94 [0.59, 1.53] |                                  |
| SAVOR-TIMI 53    | 135 8240        | 120 8173 | 1.12 [0.87, 1.44] |                                  |
| TECOS             | 157 7257        | 165 7266 | 0.95 [0.77, 1.18] |                                  |
| **Total (95% CI)** | **26807**       | **26713** | 0.96 [0.85, 1.08] |                                  |
| Total events      | 538             | 559     |                                |                                  |

Heterogeneity: Tau² = 0.00, Chi² = 2.28, df = 5 (P = 0.81); I² = 0%

Test for overall effect: Z = 0.70 (P = 0.48)

#### C

| Study or Subgroup | DPP-4 Inhibitor | Control | Risk Ratio M-H, Random, 95% CI | Risk Ratio M-H, Random, 95% CI |
|-------------------|-----------------|---------|--------------------------------|--------------------------------|
| CARMELINA         | 209 3494        | 226 3485 | 0.92 [0.77, 1.11] |                                  |
| CAROLINA          | 112 3023        | 92 3010  | 1.21 [0.92, 1.59] |                                  |
| SAVOR-TIMI 53    | 256 8240        | 194 8173 | 1.31 [1.09, 1.57] |                                  |
| TECOS             | 200 7257        | 202 7266 | 0.99 [0.82, 1.20] |                                  |
| **Total (95% CI)** | **22014**       | **21934** | 1.09 [0.92, 1.29] |                                  |
| Total events      | 777             | 774     |                                |                                  |

Heterogeneity: Tau² = 0.02, Chi² = 8.53, df = 3 (P = 0.04); I² = 65%

Test for overall effect: Z = 0.99 (P = 0.32)

#### D

| Study or Subgroup | DPP-4 Inhibitor | Control | Risk Ratio M-H, Random, 95% CI | Risk Ratio M-H, Random, 95% CI |
|-------------------|-----------------|---------|--------------------------------|--------------------------------|
| CARMELINA         | 42 3494         | 48 3485  | 0.87 [0.58, 1.32] |                                  |
| CAROLINA          | 60 3023         | 56 3010  | 1.07 [0.74, 1.53] |                                  |
| SAVOR-TIMI 53    | 88 8240         | 75 8173  | 1.18 [0.87, 1.60] |                                  |
| TECOS             | 104 7257        | 114 7266 | 0.91 [0.70, 1.19] |                                  |
| **Total (95% CI)** | **22014**       | **21934** | 1.00 [0.85, 1.18] |                                  |
| Total events      | 295             | 293     |                                |                                  |

Heterogeneity: Tau² = 0.00, Chi² = 2.09, df = 3 (P = 0.55); I² = 0%

Test for overall effect: Z = 0.04 (P = 0.97)

#### E

| Study or Subgroup | DPP-4 Inhibitor | Control | Risk Ratio M-H, Random, 95% CI | Risk Ratio M-H, Random, 95% CI |
|-------------------|-----------------|---------|--------------------------------|--------------------------------|
| CARMELINA         | 160 3494        | 149 3485 | 1.07 [0.86, 1.33] |                                  |
| CAROLINA          | 202 3023        | 189 3010 | 1.08 [0.88, 1.30] |                                  |
| SAVOR-TIMI 53    | 395 8240        | 422 8173 | 0.93 [0.81, 1.06] |                                  |
| **Total (95% CI)** | **14757**       | **14668** | 0.99 [0.90, 1.09] |                                  |
| Total events      | 757             | 760     |                                |                                  |

Heterogeneity: Tau² = 0.00, Chi² = 1.93, df = 2 (P = 0.38); I² = 0%

Test for overall effect: Z = 0.20 (P = 0.64)
Figure 1 Effect of dipeptidyl peptidase-4 inhibitor treatment compared to control on the risk. A: Fatal and non-fatal myocardial infarction; B: Fatal and non-fatal stroke; C: Hospitalization for heart failure; D: Hospitalization due to unstable angina; E: Hospitalization for coronary revascularization; F: Cardiovascular mortality.

0.85-1.08, \( I^2 = 0\% \) and coronary revascularization (RR = 0.99, 95%CI: 0.90-1.09, \( I^2 = 0\% \)), as depicted in Figures 1B and 1E. Finally, DPP-4 inhibitors demonstrated a neutral effect on the risk for hospitalization due to unstable angina (RR = 1.00, 95%CI: 0.85-1.18, \( I^2 = 0\% \)), as shown in Figure 1D.

Regarding the risk for major cardiac arrhythmias, DPP-4 inhibitor treatment did not significantly affect the risk for atrial fibrillation (RR = 0.95, 95%CI: 0.78-1.17, \( I^2 = 0\% \)), as shown in Supplementary Figure 1A. Of note, DPP-4 inhibitors were associated with a significant increase in the risk for atrial flutter, equal to 52% (RR = 1.52, 95%CI: 1.03-2.24, \( I^2 = 0\% \)), as shown in Supplementary Figure 1B. Finally, DPP-4 inhibitors did not have a significant impact on the risk for any of the rest assessed major cardiac arrhythmias, as depicted in Supplementary Figures 1C-J.

DISCUSSION

To our knowledge, this is the first meta-analysis of recently published, large, placebo-controlled cardiovascular outcome trials broadly assessing the cardiovascular efficacy and safety of DPP-4 inhibitors in T2DM. Our meta-analysis demonstrates a rather neutral effect of DPP-4 inhibitors on the risk for myocardial infarction, hospitalization for heart failure, stroke, urgent coronary revascularization and cardiovascular death; in parallel, we highlighted the absence of a significant effect of DPP-4 inhibitors on different types of cardiac arrhythmias, except for atrial flutter, for which corresponding risk increased by 52% compared to placebo. Our results are in accordance with previous meta-analyses in the field[6,16]; nevertheless, the impact of DPP-4 inhibitors on the arrhythmic burden across patients with T2DM has not been previously evaluated.

To date, a series of previous reports have indicated some cardioprotective effects of antidiabetic treatment with DPP-4 inhibitors; these generally safe and well-tolerated regimens have been associated with a significant reduction in blood pressure and with a rather low risk for hypoglycemia compared to other categories of antidiabetic drugs, while they do not increase body weight[17,18]. It has also been shown that they reduce arterial stiffness, whereas no significant effect on endothelial function was documented[19]. Additionally, in animal models, DPP-4 inhibitors have been shown to stabilize cardiac electrophysiology by decreasing the total number of premature ventricular contractions and demonstrating an antiapoptotic effect, significantly reducing the infarct size in experimental myocardial ischemia[20,21]. However, the above cardioprotective effects were not clearly translated into clinically significant results in relevant cardiovascular outcome trials and in our meta-analysis, as well.

Of particular interest is the finding of our analysis that DPP-4 inhibitors are associated with a significant increase in the risk for atrial flutter. Underlying pathophysiologic mechanisms remain largely unknown, since there are no relevant published data. However, it is well-established that diabetes mellitus increases the odds for atrial flutter development, almost by two times, as derived from epidemiological data two decades before[22]. In addition, it is known that atrial flutter at baseline is strongly associated with a significant increase in the 10-year risk for myocardial infarction, stroke, heart failure and all-cause death among affected subjects, constituting this arrhythmia as a prognostic marker of future adverse
cardiovascular outcomes\[23\]. Therefore, the observation that DPP-4 inhibitors actually increase the risk for atrial flutter is of utmost importance that may influence decision-making concerning high-risk patients, such as those suffering from T2DM.

The importance of documenting a neutral effect on a surrogate, prespecified endpoint for a drug class is as important as demonstrating a positive or negative effect, since knowledge about the risk to benefit profile of each different class plays a crucial role in decision-making process in daily clinical routine\[24\]. Furthermore, considering CVOTs demonstrating significant cardiovascular and renal benefits of other classes of glucose-lowering agents, namely sodium glucose cotransporter-2 inhibitors and glucagon-peptide-1 receptor agonists\[25,26\], in patients with T2DM, it is important that all such information is incorporated into the clinical guidelines, which have already incorporated these results in their latest recommendations\[27,28\].

**CONCLUSION**

In conclusion, DPP-4 inhibitors do not confer any significant cardiovascular benefit for patients with T2DM. In addition, they are not associated with a significant risk for any major cardiac arrhythmias, except for atrial flutter. However, this drug class should not be the treatment of choice for patients with established cardiovascular disease or multiple risk factors, except for those cases when newer antidiabetics (glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors) are not tolerated, contraindicated or not affordable for the patient.

**ARTICLE HIGHLIGHTS**

**Research background**
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a safe and efficacious treatment option in type 2 diabetes mellitus (T2DM).

**Research motivation**
Recently, several large, cardiovascular-outcome, randomized controlled trials (RCTs) with DPP-4 inhibitors in patients with T2DM have been published, raising some doubts on the cardiovascular efficacy and safety of this drug class.

**Research objectives**
Herein the authors provide the most updated and broad relevant meta-analysis by pooling data of interest from the available cardiovascular-outcome RCTs, addressing the cardiovascular efficacy and safety of this drug class.

**Research methods**
The authors searched PubMed and grey literature sources for all published RCTs assessing cardiovascular outcomes with DPP-4 inhibitors compared to placebo until October 2020.

**Research results**
Overall, DPP-4 inhibitors seem to have a neutral effect on most surrogate cardiovascular outcome endpoints, such as cardiovascular death, myocardial infarction, stroke, hospitalization for heart failure decompensation, hospitalization for unstable angina or coronary revascularization.

**Research conclusions**
DPP-4 inhibitors do not provide any clear cardiovascular benefit in patients with T2DM. Notably, DPP-4 inhibitors are not associated with a significant effect on the risk for major cardiac arrhythmias, except for atrial flutter, increasing the risk by 52% compared to placebo.

**Research perspectives**
DPP-4 inhibitors do not provide any clear cardiovascular benefit in patients with T2DM.
REFERENCES

1. Einhorn TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. *Cardiovasc Diabetol* 2018; 17: 83 [PMID: 29884191 DOI: 10.1186/s12933-018-0728-6]

2. Englert SE, van der Graaf Y, Stam-Slob MC, Grobbe DE, Cramer MJ, Kappelle LJ, de Borst GJ, Visseren FLJ, Westerink J. SMART study group. Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes. *Int J Cardiol* 2017; 248: 301-307 [PMID: 28802735 DOI: 10.1016/j.ijcard.2017.07.081]

3. Einhorn TR, Acs A, Ludwig C, Panton UH. Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review. *Value Health* 2018; 21: 881-890 [PMID: 30057671 DOI: 10.1016/j.jval.2017.12.019]

4. Grisanti LA. Diabetes and Arrhythmias: Pathophysiology, Mechanisms and Therapeutic Outcomes. *Front Physiol* 2018; 9: 1669 [PMID: 30534081 DOI: 10.3389/fphys.2018.01669]

5. Fei Y, Tsoi MF, Cheung BMY. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. *Cardiovasc Diabetol* 2019; 18: 112 [PMID: 31462224 DOI: 10.1186/s12933-019-0916-z]

6. Sinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. *Diabetes Res Clin Pract* 2019; 150: 8-16 [PMID: 30794833 DOI: 10.1016/j.diabres.2019.02.014]

7. Alfayez OM, Almutairi AR, Alosaari A, Al Yami MS. Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials. *Can J Diabetes* 2019; 43: 538-545.e2 [PMID: 31175007 DOI: 10.1016/j.jcjd.2019.04.003]

8. Higgins JPT GS, Green S. Cochrane Handbook for Systematic Reviews of Interventions. *Cochrane Database Syst Rev* 2010; 6: 143-148

9. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li, McAleenan A, Reeves BC, Shrier I, Stewart LA, Tilling KM, White WB. *Cochrane Handbook for Systematic Reviews of Interventions*. Cochrane

10. Rosenstock J, Kahn SE, Johansen OE, Zinnman B, Espeland MA, Woerle HJ, Pfarr E, Keller A, Mattheus M, Baastrup D, Meinicke T, George JT, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK, Marx N; CAROLINA Investigators. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CAROLINA Randomized Clinical Trial. *JAMA* 2019; 321: 69-79 [PMID: 30418475 DOI: 10.1001/jama.2018.18269]

11. Gantz I, Chen M, Suryawanshi S, Ntabadde C, Shah S, O'Neill EA, Engel SS, Kaufman KD, Lai E. A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus. *Cardiovasc Diabetol* 2017; 16: 112 [PMID: 28893244 DOI: 10.1186/s12933-017-0593-y]

12. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Friedrich R, Wiviott SD, Hoffman EJ, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med* 2013; 369: 1317-1326 [PMID: 23992601 DOI: 10.1056/NEJMoa1307684]

13. White WB, Cannon CP, Hoggard SR, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kugler S, Wilson C, Cushman WC, Zannad F; EXAMINE Investigators. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. *Cardiovasc Diabetol* 2017; 16: 112 [PMID: 28893244 DOI: 10.1186/s12933-017-0593-y]

14. Liu D, Jin B, Chen W, Yun P. Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis. *BMC Pharmacol Toxicol* 2019; 20: 15 [PMID: 30832701 DOI: 10.1186/s40360-019-0293-y]

15. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. *BMJ* 2012; 344: e1369 [PMID: 22411919 DOI: 10.1136/bmj.e1369]

16. Papagianni M, Tziomalos K. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors. *Hippokratia* 2015; 19: 195-199 [PMID: 27418775]
19 Batzias K, Antonopoulos AS, Oikonomou E, Siasos G, Bletsas E, Stampouloglou PK, Mistakidi CV, Noutsou M, Katsiki N, Karopoulou P, Charalambous G, Thanopoulou A, Touloumi N, Tousoulis D. Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis. *J Diabetes Res* 2018; 2018: 1232583 [PMID: 30622967 DOI: 10.1155/2018/1232583]

20 Chinda K, Palee S, Surinakaew S, Phornphutkul M, Chattipakorn S, Chattipakorn N. Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury. *Int J Cardiol* 2013; 167: 451-457 [PMID: 22285447 DOI: 10.1016/j.ijcard.2012.01.011]

21 Kubota A, Takano H, Wang H, Hasegawa H, Kadokoro H, Hirose M, Kobara Y, Yamada-Inagawa T, Kornuro I, Kobayashi Y. DPP-4 inhibition has beneficial effects on the heart after myocardial infarction. *J Mol Cell Cardiol* 2016; 91: 72-80 [PMID: 26739213 DOI: 10.1016/j.yjmcc.2015.12.026]

22 Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. *Int J Cardiol* 2005; 105: 315-318 [PMID: 16274775 DOI: 10.1016/j.ijcard.2005.02.050]

23 Rahman F, Wang N, Yin X, Ellinor PT, Lubitz SA, LeLorier PA, McManus DD, Sullivan LM, Seshadri S, Vasan RS, Benjamin EJ, Magnani JW. Atrial flutter: Clinical risk factors and adverse outcomes in the Framingham Heart Study. *Heart Rhythm* 2016; 13: 233-240 [PMID: 26226213 DOI: 10.1016/j.hrthm.2015.07.031]

24 Chi C, Snith J, Gunton JE. Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes. *Heart Lung Circ* 2017; 26: 1133-1141 [PMID: 28473214 DOI: 10.1016/j.hlc.2017.02.030]

25 Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahm A, Furtado RH, Bhatt DL, Leifer LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet* 2019; 393: 31-39 [PMID: 30424892 DOI: 10.1016/S0140-6736(18)32590-X]

26 Giugliano D, Maiorino MJ, Bellastella G, Longo M, Chiodini P, Esposito K. GLP-1 receptor agonists for prevention of cardioirenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials. *Diabetes Obes Metab* 2019; 21: 2576-2580 [PMID: 31373167 DOI: 10.1111/dom.13847]

27 American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. *Diabetes Care* 2020; 43: S98-S110 [PMID: 31862752 DOI: 10.2337/dci20-S009]

28 Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, D’Alessio DA, Davies MJ. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2020; 43: 487-493 [PMID: 31857443 DOI: 10.2337/dci19-0066]
